[1] |
Fernández-Vigo JI,Gómez-de-Liaño CN,Rodríguez-Quet O,et al.Clinical update in nanophthalmos:Features,diseases and complications associated[J].Arch Soc Esp Oftalmol(Engl Ed),2023,98(12):687-702.
|
[2] |
Carricondo PC,Andrade T,Prasov L,et al.Nanophthalmos:A Review of the Clinical Spectrum and Genetics[J].JOphthalmol,2018:2735465.
|
[3] |
Rajendrababu S, Wijesinghe HK, Uduman MS, et al. A comparative study on endothelial cell loss in nanophthalmic eyes undergoing cataract surgery by phacoemulsification[J].Indian J Ophthalmol,2021,69(2):279-285.
|
[4] |
Yang N,Jin S,Ma L,et al.The Pathogenesis and Treatment of Complications in Nanophthalmos[J]. J Ophthalmol,2020:6578750.
|
[5] |
Duke-Elder S.Normal and Abnormal Development;Congenital Deformities.Part 2.Congenital deformities[J].J Med Educ,1964,39:867.
|
[6] |
Day AC,Khawaja AP,Peto T,er al.The small eye phenotype in the EPIC-Norfolk eye study:prevalence and visual impairment in microphthalmos and nanophthalmos[J].BMJ Open,2013,3(7):e003280.
|
[7] |
Garnai SJ,Brinkmeier ML,Emery B,et al.Variants in myelin regulatory factor(MYRF) cause autosomal dominant and syndromic nanophthalmos in humans and retinal degeneration in mice[J].PLoSGenet,2019,15(5):e1008130.
|
[8] |
Tao J,Jin ZB,Shen RJ.MFRP,PRSS56,and MYRF account for 60.5% of a Chinese cohortwith nanophthalmos[J].Clin Exp Ophthalmol,2025,53(2):194-208.
|
[9] |
Kovacs KD,Van Tassel SH,Gupta MP.Novel Mfrp Mutation With Nanophthalmos, Optic Disk Drusen, And Peripheral Retinoschisis Imaged With Ultra-Widefield Optical Coherence Tomography[J].Retin Cases Brief Rep,2023,17(3),269-272.
|
[10] |
Koenighofer M,Parzefall T,Frohne A,et al.A novel proline substitution(Arg201Pro)in alpha helix 8 of TMEM98 causes autosomal dominant nanophthalmos-4,closed angle glaucoma and attenuated visual acuity[J].Exp Eye Res,2021,205:108497.
|
[11] |
Gass JD.Uveal effusion syndrome:a new hypothesis concerning pathogenesis and technique of surgical treatment.1983.Retina[J].2003,23(6 Suppl):159-163.
|
[12] |
Shah SP,Taylor AE,Sowden JC,et al.Surveillance of Eye Anomalies(SEA-UK)Special Interest Group.Anophthalmos,microphthalmos,and typical coloboma in the United Kingdom:a prospective study of incidence and risk[J].InvestOphthalmol Vis Sci,2011,52(1):558-564.
|
[13] |
Yu X, Zhao Z, Zhang D, et al. Anterior vitrectomy,phacoemulsification cataract extraction and irido-zonulo-hyaloidvitrectomy in protracted acute angle closure crisis[J].Int Ophthalmol,2021,41(9):3087-3097.
|
[14] |
Elder MJ.Aetiology of severe visual impairment and blindness in microphthalmos[J].Br JOphthalmol,1994,78(5):332-334.
|
[15] |
Wu W,Dawson DG,Sugar A,et al.Cataract surgery in patients with nanophthalmos:Results and complications[J].J Cataract Refract Surg,2004,30:584-590.
|
[16] |
Yalvac IS,Satana B,Ozkan G,et al.Management of glaucoma in patientswith nanophthalmos[J].Eye(Lond),2008,22(6):838-843.
|
[17] |
Zhang Z,Zhang S,Jiang X,et al.Combined 23-G pars plana vitrectomy and lensectomy in the management of glaucoma associated with nanophthalmos[J].Ophthalmic Res,2018,59(1):37-44.
|
[18] |
Yang N,Zhao LL,Liu J,er al.Nanophthalmos:An Update on the Biological Parameters and Fundus Abnormalities[J].J Ophthalmol,2021:8853811.
|
[19] |
Uyama M,Takahashi K,Kozaki J,et al.Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiology[J].Ophthalmology,2000,107(3):441-449.
|
[20] |
González-Martín-Moro J,gutierrez-ortiz C.Implications of SSOCT-anterior scleral thickness biometry on the definition of nanophthtalmos[J].Clin Exp Optom,2022,105:452.
|
[21] |
Rajendrababu S,Shroff S,Uduman MS,et al.Clinical spectrum and treatment outcomes of patients with nanophthalmos[J].Eye(Lond),2021,35(3):825-830.
|
[22] |
魏伟,肖辉,陈立明,等.真性小眼球眼球生物学参数测量及其与眼轴长度的关系[J].中华实验眼科杂志,2019,37(9):745-749.
|
[23] |
Nowilaty SR,Mousa A,Ghazi NG.The posterior pole and papillomacular fold in posterior microphthalmos:novel spectraldomain optical coherence tomography findings.Ophthalmology[J].2013,120(8):1656-1664.
|
[24] |
Relhan N,Jalali S,Pehre N,et al.High-hyperopia database,part I: clinical characterisation including morphometric(biometric) differentiation of posterior microphthalmos from nanophthalmos[J].Eye(Lond),2016,30(1):120-126.
|
[25] |
Guo C,Zhao Z,Zhang D,et al.Anterior Segment Features in NanophthalmosWith Secondary Chronic Angle Closure Glaucoma:An Ultrasound Biomicroscopy Study[J].Invest Ophthalmol Vis Sci,2019,60(6):2248-2256.
|
[26] |
Fernández-Vigo JI,Rodríguez-Quet O,Montolío-Marzo E,et al.Anterior Scleral Thickness and Other Dimensions in Nanophthalmos by Swept-Source Optical Coherence Tomography:A Comparative Study[J].JClin Med,2023,12(17):5564.
|
[27] |
Lam A,Sambursky RP,Maguire JI.Measurement of scleral thickness in uveal effusion syndrome[J].Am J Ophthalmol,2005,140:329-331.
|
[28] |
Niazi S,Dhubhghaill SN,Doroodgar F,et al.Insight into small eyes:a practical description from phenotypes presentations to the management[J].Int JOphthalmol,2024,17(2):380-391.
|
[29] |
Relhan N,Jalali S,Pehre N,et al.High-hyperopia database,part I: clinical characterisation including morphometric(biometric) differentiation of posterior microphthalmos from nanophthalmos[J].Eye(Lond),2016,30(1):120-126.
|
[30] |
Rajendrababu S, Vaishali V, Senthilkumar VA, et al.Comparison of clinical and biometric characteristics between nanophthalmic children and age-matched controls[J].Indian J Ophthalmol,2022,70(7):2440-2445.
|
[31] |
汤悠,张美霞.真性小眼球研究现状与进展[J].中华眼底病杂志,2020,36(5):400-403.
|
[32] |
Elagouz M,Stanescu-Segall D,Jackson TL.Uveal effusion syndrome[J].Surv Ophthalmol,2010,55(2):134-145.
|